Novo Nordisk launches oral Wegovy weight-loss remedy throughout US

THE WHAT? Novo Nordisk has begun broad US distribution of Wegovy capsule, the primary oral GLP-1 remedy accepted for continual weight administration in adults with weight problems or chubby with associated medical circumstances.

THE DETAILS The once-daily oral formulation of semaglutide obtained FDA approval on December 22, 2025 and is now obtainable by means of greater than 70,000 US pharmacies, together with CVS and Costco, in addition to chosen telehealth platforms and on-line pharmacy companies.

Scientific information from the Part III OASIS 4 trial confirmed common weight lack of roughly 17 p.c at 64 weeks amongst sufferers who remained on remedy, in contrast with round 3 p.c for placebo. When together with all trial members no matter remedy adherence, common weight reduction was roughly 14 p.c, versus 2 p.c for placebo.

The beginning dose of 1.5 mg is being provided by way of a self-pay programme at US$149 monthly, with tiered pricing for larger doses. Novo Nordisk mentioned the protection profile noticed in OASIS 4 was in line with earlier injectable Wegovy trials, with gastrointestinal results among the many mostly reported adversarial reactions.

THE WHY? The launch marks a major growth of the GLP-1 market past injectable therapies, probably broadening entry and adoption amongst sufferers reluctant to make use of injections. For client well being, diet and beauty-adjacent sectors, the rollout highlights the rising convergence of pharmaceutical weight administration, wellness and long-term life-style intervention, as demand for weight problems remedies accelerates within the US. Elevated availability and decrease entry pricing might additional intensify competitors throughout the quickly increasing weight-loss class.

Supply: Novo Nordisk